GeneDx (NASDAQ:WGS) versus Cannlabs (OTCMKTS:CANL) Critical Contrast

GeneDx (NASDAQ:WGS) and Cannlabs (OTCMKTS:CANL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Institutional & Insider Ownership

61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

GeneDx has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Cannlabs has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Earnings & Valuation

This table compares GeneDx and Cannlabs”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$305.45 million	13.29	-$52.29 million	$0.09	1,560.44
Cannlabs	N/A	N/A	N/A	N/A	N/A

Cannlabs has lower revenue, but higher earnings than GeneDx.

Profitability

This table compares GeneDx and Cannlabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	0.52%	20.22%	11.89%
Cannlabs	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for GeneDx and Cannlabs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	3	7	0	2.55
Cannlabs	0	0	0	0	0.00

GeneDx presently has a consensus target price of $134.78, suggesting a potential downside of 4.03%. Given Cannlabs’ higher possible upside, analysts plainly believe Cannlabs is more favorable than GeneDx.

Summary

GeneDx beats Cannlabs on 9 of the 10 factors compared between the two stocks.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About Cannlabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.